These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7022829)

  • 1. Preparation of xenogeneic antibodies eliminating lymphocytes from human bone marrow selectively.
    Wulff JC; Anderson M; Held H; Müller-Hermelink HK; Schlaak M; Müller-Ruchholtz W
    Transplant Proc; 1981 Mar; 13(1 Pt 1):230-3. PubMed ID: 7022829
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of graft-versus-host disease by Fab fragments derived from ALG.
    Richie ER; Gallagher MT; Trentin JJ
    Transplant Proc; 1973 Mar; 5(1):873-6. PubMed ID: 4144467
    [No Abstract]   [Full Text] [Related]  

  • 3. Antilymphocytic antibodies and marrow transplantation. IV. Comparison of the effects of antibody fragments directed against immunoglobulin or lymphocyte antigens on acute secondary disease.
    Rodt H; Therfelder S; Eulitz M
    Exp Hematol; 1974; 2(4):195-203. PubMed ID: 4156327
    [No Abstract]   [Full Text] [Related]  

  • 4. Delayed secondary disease in mice after early or late therapy with anti-thymocyte serum.
    Kinnamon KE; Blackwell LH; Ledney GD
    Exp Hematol; 1973; 1(4):202-14. PubMed ID: 4154088
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of acute graft-versus-host (GVH) mortality with spleen-absorbed antithymocyte globulin (ATG).
    Trentin JJ; Judd KP
    Transplant Proc; 1973 Mar; 5(1):865-8. PubMed ID: 4540468
    [No Abstract]   [Full Text] [Related]  

  • 6. [Letter: Lichen eruptions after allogenic bone marrow graft].
    Saurat JH; Gluckman E; Bussel A; Didier-Jean L
    Nouv Presse Med; 1975 Mar; 4(10):745 (1). PubMed ID: 236539
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antilymphocyte serum as an immunosuppressant].
    Wiig JN
    Tidsskr Nor Laegeforen; 1973 Mar; 93(9):574-8. PubMed ID: 4148532
    [No Abstract]   [Full Text] [Related]  

  • 8. [Our method for the production of antilymphocyte serum and the results of its experimental use].
    Metscharski St; Vasvasov N; Maimunkov K; Mozev D
    Z Exp Chir; 1972; 5(1):25-7. PubMed ID: 4156944
    [No Abstract]   [Full Text] [Related]  

  • 9. The rhesus monkey as a preclinical model for bone marrow transplantation.
    van Bekkum DW
    Transplant Proc; 1978 Mar; 10(1):105-11. PubMed ID: 416528
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antilymphocyte serum: production, basic properties and clinical use (review of the literature)].
    Shabalin VN
    Vestn Khir Im I I Grek; 1972 Aug; 109(8):131-6. PubMed ID: 4126160
    [No Abstract]   [Full Text] [Related]  

  • 11. Modification of graft-vs-host disease following bone marrow transplantation in germfree mice.
    Bealmear PM; Mirand EA; Holtermann OA
    Prog Clin Biol Res; 1983; 132C():409-21. PubMed ID: 6227014
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective antilymphocyte sera (SAL) in bone marrow transplantation. I. In vitro characterization of antihuman SAL and the development of absorption procedures using cultured cell lines.
    Anderson MJ; Schmitz N; Müller-Hermelink HK; Müller-Ruchholtz W
    Int Arch Allergy Appl Immunol; 1985; 76(3):218-25. PubMed ID: 3882571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of monoclonal antibodies in human bone marrow transplantation.
    Neudorf SM; Filipovich AH; Kersey JH
    Prog Clin Biol Res; 1984; 149():367-77. PubMed ID: 6377327
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential inactivation of lymphocytes and bone marrow stem cells by heterologous anti-mouse gamma-globulin serum.
    Cole LJ; Maki SE
    Nat New Biol; 1971 Apr; 230(16):244-6. PubMed ID: 4396811
    [No Abstract]   [Full Text] [Related]  

  • 15. An antithymocyte serum noncytotoxic to myeloid progenitor cells: candidate serum for prevention of graft-versus-host disease in bone marrow transplantation.
    Foon KA; Fitchen JH; Billing RJ; Belzer MB; Terasaki PI; Cline MJ
    Clin Immunol Immunopathol; 1980 Aug; 16(4):416-22. PubMed ID: 6996874
    [No Abstract]   [Full Text] [Related]  

  • 16. Possibility of three distinct and separable components to fatal graft-vs-host reaction.
    Okunewick JP; Meredith RF; Raikow RB; Buffo MJ; Jones DL
    Exp Hematol; 1982 Mar; 10(3):277-91. PubMed ID: 7040093
    [No Abstract]   [Full Text] [Related]  

  • 17. [The importance of antilymphocyte serum in immunosuppression].
    Pichlmayr R
    Langenbecks Arch Chir; 1968; 322():485-95. PubMed ID: 4394915
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical trial of antithymocyte globulin for prophylaxis of acute graft-versus-host disease in pediatric recipients of bone marrow transplantation from unrelated donors].
    Yagasaki H; Kojima S; Inaba J; Kato K; Matsuyama T
    Rinsho Ketsueki; 1999 May; 40(5):382-9. PubMed ID: 10390886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitigation of graft-versus-host disease in rats treated with allogeneic and xenogeneic antilymphocytic sera.
    Werner C; Ramirez E; Gervasoni C; Jeannet M
    Experientia; 1976 Feb; 32(2):241-2. PubMed ID: 5281
    [No Abstract]   [Full Text] [Related]  

  • 20. [Protective effect of antisera against homograft reaction and other immunologic injuries].
    Benkö A
    Z Gesamte Inn Med; 1971 Aug; 26(15):479-83. PubMed ID: 4110569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.